Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy
Jesús G. Berdeja(Tennessee Oncology), Ian W. Flinn(Tennessee Oncology), Todd M. Bauer(Tennessee Oncology), James Essell(Oncology Hematology Care), Michael R. Savona(Vanderbilt University), Luis Chu(Sarah Cannon), Eric Raefsky(Tennessee Oncology), Ralph V. Boccia(Center for Cancer and Blood Disorders), Patrick B. Murphy(Wisconsin Heart Hospital)
Cited by 7
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k